HOPE Therapeutics Expands Neuropsychiatry Footprint with Strategic Acquisition in Florida

HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc., has taken a significant step towards expanding its footprint in the interventional psychiatry market by entering into a binding letter of intent to acquire a 49% stake in Cohen and Associates, LLC. This acquisition is not only expected to be immediately accretive to revenue and EBITDA but also marks a pivotal moment in HOPE Therapeutics' strategy to enhance its clinical offerings and market presence in Florida.

Cohen and Associates, LLC, located in the Sarasota-Bradenton area, is renowned for its specialized treatments in mood disorders, PTSD, and suicidal depression, utilizing advanced therapies such as ketamine infusions and transcranial magnetic stimulation (TMS). Under the leadership of Dr. Rebecca Cohen, the clinic has established itself as a cornerstone of comprehensive psychiatric care services in western Florida.

This acquisition is a key component of HOPE Therapeutics' ambitious plan to expand its network to 30 clinics, with the goal of achieving a $100 million run rate by the end of 2025. By integrating Cohen and Associates into its network, HOPE Therapeutics is not only broadening its clinical capabilities but also reinforcing its commitment to providing cutting-edge psychiatric care. For more information on NRx Pharmaceuticals and its subsidiaries, investors are encouraged to visit the company's newsroom at https://ibn.fm/NRXP.